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1. INTRODUCTION {#brb31426-sec-0005}
===============

Stroke is one of leading causes of mortality and long‐term morbidity in China (Feigin et al., [2014](#brb31426-bib-0009){ref-type="ref"}). Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator administered up to 4.5 hr after onset has demonstrated benefits for acute ischemic stroke (AIS) with proven efficacy in reducing mortality and long‐term morbidity (National Institute of Neurological Disorders & Stroke rt‐PA Stroke Study Group, [1995](#brb31426-bib-0020){ref-type="ref"}). However, within 24 hr after IVT, a fraction of patients may experience neurological deficit worsening, described as early neurological deterioration (END; Seners et al., [2017](#brb31426-bib-0023){ref-type="ref"}, [2014](#brb31426-bib-0025){ref-type="ref"}), which has been reported to be associated with poor outcomes (Mori et al., [2012](#brb31426-bib-0018){ref-type="ref"}). Thus, it is of great importance to explore the mechanism and the associated risk factors for post‐thrombolysis END.

Inflammation plays an important role in the pathophysiology of cerebrovascular diseases (Barone et al., [1991](#brb31426-bib-0003){ref-type="ref"}; Zhang et al., [2016](#brb31426-bib-0030){ref-type="ref"}). Except for the cytokines and chemokines released from in situ ischemic tissues, infiltration of peripheral circulating leukocytes, especially neutrophils, has been regarded as an important contributor to brain injury following ischemia (Qun et al., [2017](#brb31426-bib-0021){ref-type="ref"}). Several studies have confirmed the pivotal role of neutrophils in functional outcome after AIS (Gusdon et al., [2017](#brb31426-bib-0011){ref-type="ref"}; Wu et al., [2013](#brb31426-bib-0028){ref-type="ref"}). Neutrophil--lymphocyte ratio (NLR), a novel inflammatory marker that can be easily calculated from the differential white blood cell (WBC) count, was reported to be associated with the mortality and long‐term disability in stroke population (Gusdon et al., [2017](#brb31426-bib-0011){ref-type="ref"}; Köklü et al., [2016](#brb31426-bib-0015){ref-type="ref"}; Qun et al., [2017](#brb31426-bib-0021){ref-type="ref"}; Tokgoz et al., [2013](#brb31426-bib-0027){ref-type="ref"}). Also, high levels of NLR had a predictive value for 90‐day outcome of stroke patients treated with endovascular therapy (Brooks et al., [2014](#brb31426-bib-0004){ref-type="ref"}). However, there is a lack of data regarding the relationship between NLR and END in ischemic stroke patients underwent IVT. Therefore, we performed this prospectively observational study to explore the utility of NLR in predicting END after IVT.

2. METHODS {#brb31426-sec-0006}
==========

2.1. Study population {#brb31426-sec-0007}
---------------------

This prospective study was performed from October 2016 to March 2018 in Nanjing First Hospital. Patients with first‐ever AIS treated with IVT within 4.5 hr after symptom onset were included in the study. Patients treated with a bridging therapy consisting of IVT followed by endovascular therapy were also included. The exclusion criteria were as follows: (a) age \<18 years and (b) unstable medical conditions such as systemic inflammatory disease, renal failure, hepatic failure, brain tumor, and presence of an active infection. Patients with hospital transfer were also excluded. Informed consent was obtained from participants or legal representatives, and the protocol was approved by the Ethical Committee of Nanjing First Hospital.

2.2. Clinical assessments {#brb31426-sec-0008}
-------------------------

Clinical assessments were performed within 24 hr after admission. All participants had standard assessments of demographic characteristics, vascular risk factors (including hypertension, diabetes mellitus, dyslipidemia, current smoking, current drinking, previous stroke, atrial fibrillation, and coronary heart disease), stroke severity, stroke subtype, and laboratory data. Symptomatic intracranial hemorrhage (sICH) was defined as any hemorrhagic transformation associated with NIHSS score worsening ≥4 points. Malignant edema was considered if brain was swelling and midline shift was present together with worsening of consciousness. Computed tomography, magnetic resonance and digital subtraction angiography, and electrocardiogram, transcranial Doppler, and carotid ultrasonography were performed for assessing the stroke etiology. Stroke subtype was classified according to Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria (Adams et al., [1993](#brb31426-bib-0001){ref-type="ref"}). Blood cell counts, including total leukocyte, neutrophil, and lymphocyte counts, and clotting routine were sampled from each participant in stroke emergency room on admission. Then, the cell counts were analyzed by an auto‐analyzer (XE‐2100, Sysmex). NLR was calculated as neutrophil counts/lymphocyte counts.

2.3. Definition of END {#brb31426-sec-0009}
----------------------

The evaluation of neurological deficits was conducted using the National Institutes of Health Stroke Scale (NIHSS) score on admission and continued at the following 24 hr after IVT by two certified neurologists blind to clinical data. Post‐thrombolysis END was defined as a NIHSS score increase of ≥4 points between baseline and the 24 hr after IVT (Mori et al., [2012](#brb31426-bib-0018){ref-type="ref"}; Seners et al., [2017](#brb31426-bib-0023){ref-type="ref"}, [2014](#brb31426-bib-0025){ref-type="ref"}).

2.4. Treatment {#brb31426-sec-0010}
--------------

All patients were treated with IVT within 4.5 hr after the onset of stroke symptoms in stroke emergency room. Once proximal arterial occlusion had been corroborated via magnetic resonance angiography or CTA, the participants would undergo rapid endovascular treatment. Other treatments, such as risk factor management and statin therapy, were also carried out as appropriate.

2.5. Statistical analysis {#brb31426-sec-0011}
-------------------------

Statistical analyses were performed with SPSS version 21.0 (SPSS Inc.). Continuous variables that followed normal distribution were expressed as mean ± standard deviation; other continuous variables that did not follow normal distributions were presented as the median and the interquartile range (25th to 75th percentile). Categorical variables are expressed as constituent ratios. Differences in baseline characteristics were tested using the analysis of variance or Kruskal--Wallis test for continuous variables, and Pearson\'s chi‐square test for categorical variables. We also used binary logistic regression analysis to detect the risk factors of END. Multivariable analysis was adjusted for all potential confounders with statistically significant association at *p* \< .1 in univariate regression analysis (including age, eGFR ≤ 60 ml/min/1.73 m^2^, initial NIHSS score, malignant edema, stroke subtype, hypersensitive C‐reactive protein, and fasting blood glucose level). Receiver operating characteristic (ROC) curve analysis was performed by assessing the overall discriminative ability of the NLR to predict post‐thrombolysis END and to establish optimal cutoff points at which the sum of the specificity and sensitivity was the highest. A MedCalc 15.6.0 (MedCalc Software) packet program was used to obtain ROC. In addition, a nomogram based on the independent predictors was constructed by R software with the package rms. The predictive capacity of the nomogram was determined by Harrell\'s c‐index. A two‐tailed value of *p* \< .05 was considered significant.

3. RESULTS {#brb31426-sec-0012}
==========

From October 2016 to March 2018, 386 patients were screened in this study. Forty‐four patients were excluded for the following reasons: systemic inflammatory disease (*n* = 9), renal failure (*n* = 14), hepatic failure (*n* = 8), brain tumor (*n* = 3), and presence of an active infection (*n* = 10). A total of 342 subjects (233 men; mean age, 68.1 ± 12.3 years) were included for the final analysis. Among these patients, 238 (69.6%) had hypertension, 75 (21.9%) had diabetes mellitus, 94 (27.5%) had dyslipidemia, and 73 (21.3%) had atrial fibrillation.

After admission, END was observed in 86 patients (25.1%). The median NLR was 4.65, with tertile levels as follows: 0.66--2.27 (first tertile); 2.28--4.43 (second tertile); 4.48--35.73 (third tertile). Baseline characteristics of the study population according to the tertile of NLR are provided in Table [1](#brb31426-tbl-0001){ref-type="table"}. Increased NLR was related to post‐thrombolysis END (*p* = .001), onset‐to‐treatment time (*p* = .001), sICH (*p* = .006), malignant edema (*p* = .008), and high levels of fasting blood glucose (*p* = .008).

###### 

Characteristics of subgroups based on the tertile of neutrophil--lymphocyte ratio

  Variable                         Total (*n* = 342)      First tertile (*n* = 114)   Second tertile (*n* = 114)   Third tertile (*n* = 114)   *p*
  -------------------------------- ---------------------- --------------------------- ---------------------------- --------------------------- ------
  Demographic characteristics                                                                                                                  
  Age, years                       68.1 ± 12.3            67.6 ± 11.4                 67.9 ± 13.9                  68.7 ± 11.5                 .804
  Male, %                          233 (68.1)             80 (70.2)                   76 (66.7)                    77 (67.5)                   .839
  Vascular risk factors, %                                                                                                                     
  Hypertension                     238 (69.6)             74 (64.9)                   83 (72.8)                    81 (71.1)                   .396
  Diabetes mellitus                75 (21.9)              18 (15.8)                   33 (28.9)                    24 (21.1)                   .054
  Dyslipidemia                     94 (27.5)              26 (22.8)                   36 (31.6)                    32 (28.1)                   .328
  Current smoking                  125 (36.5)             48 (42.1)                   42 (36.8)                    35 (30.7)                   .202
  Current drinking                 94 (27.5)              33 (28.9)                   30 (26.3)                    31 (27.2)                   .902
  Previous stroke                  50 (14.6)              19 (16.7)                   17 (14.9)                    14 (12.3)                   .816
  Atrial fibrillation              73 (21.3)              21 (18.4)                   28 (24.6)                    24 (21.1)                   .525
  Coronary heart disease           65 (19.0)              16 (14.0)                   22 (19.3)                    27 (23.7)                   .188
  Clinical data                                                                                                                                
  Previous antiplatelet, %         60 (17.5)              26 (22.8)                   21 (18.4)                    13 (11.4)                   .074
  Previous statin, %               22 (6.4)               11 (9.6)                    8 (7.0)                      3 (2.6)                     .086
  eGFR ≤ 60 ml/min/1.73 m^2^, %    97 (28.4)              25 (21.9)                   34 (29.8)                    38 (33.3)                   .147
  Systolic blood pressure, mmHg    147.3 ± 22.3           147.8 ± 25.2                148.6 ± 20.8                 145.5 ± 20.6                .549
  Diastolic blood pressure, mmHg   87.4 ± 14.4            89.0 ± 16.3                 86.5 ± 13.1                  86.9 ± 13.6                 .371
  Body mass index, kg/m^2^         23.9 ± 3.4             24.1 ± 3.1                  24.2 ± 3.4                   23.6 ± 3.7                  .330
  Initial NIHSS, score             8 (3, 13)              8 (3, 12)                   6 (3, 12)                    9 (4, 15)                   .067
  OTT, min                         149.0 (104.0, 200.0)   120.0 (96.0, 170.0)         158.0 (105.0, 210.0)         180.5 (115.0, 215.0)        .001
  Proximal arterial occlusion, %   105 (32.4)             34 (29.8)                   30 (26.3)                    44 (38.6)                   .121
  Endovascular treatment, %        82 (25.3)              23 (20.2)                   24 (21.1)                    35 (30.7)                   .118
  Post‐thrombolysis END, %         86 (25.1)              12 (10.5)                   13 (11.4)                    61 (53.5)                   .001
  sICH, %                          23 (6.7)               2 (1.8)                     7 (6.1)                      14 (12.3)                   .006
  Malignant edema, %               16 (4.7)               3 (2.6)                     2 (0.6)                      11 (9.6)                    .008
  Stroke subtype, %                                                                                                                            .504
  LAA                              98 (28.7)              38 (33.3)                   28 (24.6)                    32 (28.1)                    
  CE                               91 (26.6)              30 (26.3)                   35 (30.7)                    26 (22.8)                    
  SAO                              77 (22.5)              26 (22.8)                   26 (22.8)                    25 (21.9)                    
  Others or undetermined           76 (22.2)              20 (17.5)                   25 (21.9)                    31 (27.2)                    
  Laboratory data                                                                                                                              
  TC, mmol/L                       4.4 ± 1.1              4.6 ± 1.1                   4.4 ± 1.1                    4.4 ± 1.1                   .278
  TG, mmol/L                       1.3 (0.9, 1.7)         1.3 (0.9, 2.1)              1.3 (0.9, 1.7)               1.2 (0.8, 1.6)              .081
  LDL, mmol/L                      2.7 (2.0, 3.3)         2.8 (2.1, 3.6)              2.7 (2.0, 3.4)               2.6 (1.9, 3.2)              .160
  Hs‐CRP, μg/ml                    4.6 (2.0, 8.6)         3.6 (2.0, 6.7)              4.7 (1.9, 8.4)               6.1 (2.0, 9.8)              .087
  FBG, mmol/L                      6.2 ± 2.0              5.8 ± 1.8                   6.2 ± 2.2                    6.6 ± 1.8                   .008
  Homocysteine, μmol/L             16.3 ± 8.2             16.8 ± 6.9                  15.3 ± 7.6                   16.6 ± 10.0                 .358
  Uric acid, μmol/L                308.3 ± 109.2          319.3 ± 108.9               312.6 ± 107.7                293.1 ± 110.2               .172

Abbreviations: CE, cardioembolism; eGFR, estimate glomerular filtration rate; FBG, fasting blood glucose; Hs‐CRP, hypersensitive c‐reactive protein; LAA, large artery atherosclerosis; LDL, low‐density lipoprotein; NIHSS, National Institutes of Health Stroke Scale; OTT, onset‐to‐treatment time; SAO, small artery occlusion; sICH, symptomatic intracranial hemorrhage; TC, total cholesterol; TG, triglyceride.

John Wiley & Sons, Ltd

Comparisons of baseline characteristics in patients with or without END are shown in Table [2](#brb31426-tbl-0002){ref-type="table"}. Compared with patients without post‐thrombolysis END, patients with post‐thrombolysis END were older (*p* = .016) and had higher proportions of proximal arterial occlusion (*p* = .001); lower proportions of previous antiplatelet (*p* = .020); lower levels of body mass index (*p* = .028) and triglyceride (*p* = .015); higher levels of initial NIHSS (*p* = .001), hypersensitive C‐reactive protein (*p* = .001), fasting blood glucose (*p* = .001), and NLR (*p* = .001).

###### 

Characteristics of subgroups based on the presence of post‐thrombolysis early neurological deterioration

  Variable                         END group (*n* = 86)   Non‐END group (*n* = 256)   *p*
  -------------------------------- ---------------------- --------------------------- ------
  Demographic characteristics                                                         
  Age, years                       70.9 ± 11.4            67.2 ± 12.7                 .016
  Male, %                          58 (67.4)              158 (61.7)                  .874
  Vascular risk factors, %                                                            
  Hypertension                     63 (73.3)              175 (68.4)                  .393
  Diabetes mellitus                13 (15.1)              62 (24.2)                   .078
  Dyslipidemia                     25 (29.1)              69 (27.0)                   .704
  Current smoking                  29 (33.7)              96 (37.5)                   .529
  Current drinking                 30 (34.9)              64 (25.0)                   .076
  Previous stroke                  7 (8.1)                43 (16.8)                   .100
  Atrial fibrillation              21 (24.4)              52 (20.3)                   .421
  Coronary heart disease           21 (24.4)              44 (17.2)                   .144
  Clinical data                                                                       
  Previous antiplatelet, %         8 (9.3)                52 (20.3)                   .020
  Previous statin, %               3 (3.5)                19 (7.4)                    .181
  eGFR ≤ 60 ml/min/1.73 m^2^, %    31 (36.0)              66 (25.8)                   .068
  SBP, mmHg                        145.4 ± 19.5           148.0 ± 23.1                .360
  DBP, mmHg                        86.7 ± 12.8            87.7 ± 14.9                 .563
  Body mass index, kg/m^2^         23.3 ± 3.3             24.2 ± 3.4                  .028
  Initial NIHSS, score             12 (6, 18)             7 (3, 11)                   .001
  OTT, min                         175.0 (110.0, 205.0)   141.5 (100.0, 200.0)        .068
  Proximal arterial occlusion, %   53 (61.6)              85 (33.2)                   .001
  Stroke subtype, %                                                                   .073
  LAA                              47 (54.7)              111 (43.4)                   
  CE                               21 (24.4)              69 (27.0)                    
  SAO                              6 (7.0)                45 (17.6)                    
  Others or undetermined           12 (14.0)              31 (12.1)                    
  Laboratory data                                                                     
  TC, mmol/L                       4.4 ± 1.0              4.4 ± 1.1                   .986
  TG, mmol/L                       1.1 (0.8, 1.5)         1.2 (0.9, 1.9)              .015
  LDL, mmol/L                      2.6 (2.0, 3.2)         2.7 (2.0, 3.4)              .567
  Hs‐CRP, μg/ml                    6.5 (2.8, 11.6)        3.7 (1.8, 7.5)              .001
  FBG, mmol/L                      6.9 ± 1.8              5.9 ± 1.9                   .001
  Homocysteine, μmol/L             17.2 ± 9.3             16.0 ± 7.8                  .254
  Uric acid, μmol/L                309.8 ± 111.9          307.8 ± 108.5               .886
  NLR                              6.8 (2.6, 11.8)        2.6 (1.7, 4.1)              .001

Abbreviations: CE, cardioembolism; DBP, diastolic blood pressure; eGFR, estimate glomerular filtration rate; FBG, fasting blood glucose; Hs‐CRP, hypersensitive c‐reactive protein; LAA, large artery atherosclerosis; LDL, low‐density lipoprotein; NIHSS, National Institutes of Health Stroke Scale; OTT, onset‐to‐treatment time; SAO, small artery occlusion; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.

John Wiley & Sons, Ltd

Table [3](#brb31426-tbl-0003){ref-type="table"} showed the results of logistic regression analysis for risk factors with post‐thrombolysis END. Univariate logistic regression analysis demonstrated that the highest tertile of NLR, age, previous antiplatelet, eGFR ≤ 60 ml/min/1.73 m^2^, initial NIHSS score, BMI, proximal arterial occlusion, sICH, malignant edema, hypersensitive C‐reactive protein, and fasting blood glucose level were associated with END. After adjusting for all potential confounders, the highest tertile of NLR (first quartile used as the reference value) was identified as an independent predictor for post‐thrombolysis END (odds ratio \[OR\], 6.406; 95% confidence interval \[CI\] 2.646--15.510, *p* = .002).

###### 

Logistic regression analysis for risk factors with post‐thrombolysis early neurological deterioration

  Variable                                                OR          95% CI          *p*
  ------------------------------------------------------- ----------- --------------- ------
  Crude model                                                                         
  Demographic characteristics                                                         
  Age, years                                              1.021       1.001--1.043    .046
  Male                                                    0.959       0.569--1.616    .874
  Vascular risk factors                                                               
  Hypertension                                            1.268       0.735--2.187    .394
  Diabetes mellitus                                       0.622       0.328--1.180    .146
  Dyslipidemia                                            1.029       0.596--1.775    .919
  Current smoking                                         0.848       0.507--1.417    .529
  Current drinking                                        1.495       0.881--2.536    .136
  Previous stroke                                         0.494       0.211--1.160    .105
  Atrial fibrillation                                     1.267       0.711--2.260    .422
  CHD                                                     1.549       0.859--2.794    .146
  Clinical data                                                                       
  Previous antiplatelet                                   0.402       0.183--0.885    .024
  Previous statin                                         0.438       0.126--1.517    .193
  eGFR ≤ 60 ml/min/1.73 m^2^                              1.623       0.963--2.734    .069
  SBP, mmHg                                               0.995       0.984--1.006    .359
  DBP, mmHg                                               0.995       0.978--1.012    .562
  Body mass index, kg/m^2^                                0.920       0.853--0.992    .029
  Initial NIHSS, score                                    1.083       1.044--1.123    .001
  OTT time, min                                           1.001       0.997--1.005    .570
  Proximal arterial occlusion                             3.852       2.307--6.433    .001
  sICH                                                    6.549       2.669--16.072   .001
  Malignant edema                                         2.432       0.877--6.742    .088
  TOAST subtype, %                                                                    
  LAA                                                     1.572       0.767--3.220    .217
  CE                                                      1.240       0.588--2.613    .572
  Other and undetermined                                  1.794       0.850--3.785    .125
  SAO                                                     Reference   Reference        
  Laboratory data                                                                     
  TC, mmol/L                                              1.002       0.798--1.258    .986
  TG, mmol/L                                              0.842       0.628--1.128    .248
  LDL, mmol/L                                             0.999       0.989--1.008    .770
  Hs‐CRP, μg/ml                                           1.050       1.021--1.080    .001
  FBG, mmol/L                                             1.246       1.103--1.408    .001
  Homocysteine, μmol/L                                    1.017       0.988--1.048    .256
  Uric acid, μmol/L                                       1.000       0.998--1.002    .886
  NLR distribution                                                                    
  First tertile                                           Reference   Reference        
  Second tertile                                          1.094       0.476--2.513    .832
  Third tertile                                           9.783       4.847--19.764   .001
  Adjusted model[a](#brb31426-note-0005){ref-type="fn"}                               
  NLR distribution                                                                    
  First tertile                                           Reference   Reference        
  Second tertile                                          1.101       0.401--3.025    .852
  Third tertile                                           6.406       2.646--15.510   .002

Abbreviations: CE, cardioembolism; CHD, coronary heart disease; CI, confidence interval; DBP, diastolic blood pressure; FBG, fasting blood glucose; GFR, estimate glomerular filtration rate; Hs‐CRP, hypersensitive c‐reactive protein; LAA, large artery atherosclerosis; LDL, low‐density lipoprotein; NIHSS, National Institutes of Health Stroke Scale; NLR, neutrophil--lymphocyte ratio; OR, odds ratio; OTT, onset‐to‐treatment time; SAO, small artery occlusion; SBP, systolic blood pressure; sICH, symptomatic intracranial hemorrhage; TC, total cholesterol; TG, triglyceride.

Adjusted model was controlled for age, previous antiplatelet, eGFR ≤ 60 ml/min/1.73 m^2^, initial NIHSS score, body mass index, proximal arterial occlusion, sICH, malignant edema, hypersensitive C‐reactive protein, and fasting blood glucose level.

John Wiley & Sons, Ltd

Of particular interest, IVT patients were further divided into those with and without endovascular therapy. Compared with the first tertile, NLR in the third tertile showed a higher trend for the occurrence of post‐thrombolysis END (Table [4](#brb31426-tbl-0004){ref-type="table"}; OR, 7.064; 95% CI, 3.009--16.583; *p* = .001) in patients without endovascular therapy. Furthermore, in bridging therapy group, higher NLR level remained associated with post‐thrombolysis END.

###### 

Subgroup analysis according to the patients undergoing intravenous thrombolysis with and without endovascular therapy

  NLR distribution   IVT patients with endovascular therapy (*n* = 82)   IVT patients without endovascular therapy (*n* = 260)                                      
  ------------------ --------------------------------------------------- ------------------------------------------------------- ------ ----------- --------------- ------
  First tertile      Reference                                           Reference                                                      Reference   Reference        
  Second tertile     0.950                                               0.207--4.350                                            .947   1.153       0.424--3.135    .781
  Third tertile      22.958                                              5.712--92.279                                           .001   7.064       3.009--16.583   .001

Abbreviations: CI, confidence interval; IVT, intravenous thrombolysis; NLR, neutrophil--lymphocyte ratio; OR, odds ratio.

John Wiley & Sons, Ltd

As for the clinical value of NLR in predicting post‐thrombolysis END, we performed ROC curve in Figure [1](#brb31426-fig-0001){ref-type="fig"}. The optimal cutoff value for NLR as a predictor of post‐thrombolysis END was determined as 4.43 in the ROC curve analysis, which yielded a sensitivity of 70.9% and a specificity of 79.3%, with the AUC at 0.779 (95% CI, 0.731--0.822).

![Receiver operating characteristic (ROC) curve for the value of neutrophil--lymphocyte ratio (NLR) to predict post‐thrombolysis early neurological deterioration (END)](BRB3-9-e01426-g001){#brb31426-fig-0001}

The nomogram is shown in Figure [2](#brb31426-fig-0002){ref-type="fig"}. The concordance index of this model was 0.789 (*p* \< .001). The novel models indicated that higher NLR was an indicator of post‐thrombolysis END. These findings were similar to those obtained previously in the multivariate logistic models.

![Nomograms of acute ischemic stroke patients to predict post‐thrombolysis early neurological deterioration (END)](BRB3-9-e01426-g002){#brb31426-fig-0002}

We divided the patients into group A (NLR \< 4.43) and group B (NLR ≥ 4.43). Comparisons of characteristics based on the two groups are shown in Table [5](#brb31426-tbl-0005){ref-type="table"}. Compared with group B, patients in group A had less time from onset to treatment (*p* = .003), higher proportions of previous statin (*p* = .034) and proximal arterial occlusion (*p* = .001), higher levels of triglyceride (*p* = .034), lower levels of hypersensitive C‐reactive protein (*p* = .033), and fasting blood glucose (*p* = .007).

###### 

Characteristics of group A and group B

  Variable                         Group A (*n* = 227)    Group B (*n* = 115)    *p*
  -------------------------------- ---------------------- ---------------------- ------
  Demographic characteristics                                                    
  Age, years                       67.8 ± 12.8            68.8 ± 11.7            .502
  Male, %                          155 (68.2)             78 (67.8)              .932
  Vascular risk factors, %                                                       
  Hypertension                     156 (68.7)             82 (71.3)              .624
  Diabetes mellitus                50 (22.0)              25 (21.7)              .952
  Dyslipidemia                     62 (27.3)              32 (27.8)              .920
  Current smoking                  90 (39.6)              35 (30.4)              .095
  Current drinking                 62 (27.3)              32 (27.8)              .920
  Previous stroke                  36 (15.9)              14 (12.2)              .489
  Atrial fibrillation              48 (21.1)              25 (21.1)              .899
  Coronary heart disease           38 (16.7)              27 (23.5)              .139
  Clinical data                                                                  
  Previous antiplatelet, %         46 (21.6)              14 (12.2)              .063
  Previous statin, %               19 (8.4)               3 (2.6)                .034
  eGFR ≤ 60 ml/min/1.73 m^2^, %    59 (26.0)              38 (33.0)              .172
  SBP, mmHg                        148.3 ± 23.1           145.4 ± 20.5           .264
  DBP, mmHg                        87.7 ± 14.8            86.9 ± 13.6            .607
  Body mass index, kg/m^2^         24.2 ± 3.3             23.6 ± 3.6             .154
  Initial NIHSS, score             7 (3, 12)              9 (4, 15)              .052
  OTT, min                         130.0 (100.5, 192.5)   183.0 (116.5, 215.0)   .003
  Proximal arterial occlusion, %   77 (33.9)              61 (53.0)              .001
  Stroke subtype, %                                                              .076
  LAA                              98 (43.2)              60 (52.2)               
  CE                               64 (28.2)              26 (22.6)               
  SAO                              40 (17.6)              11 (9.6)                
  Others or undetermined           25 (11.0)              18 (15.7)               
  Laboratory data                                                                
  TC, mmol/L                       4.5 ± 1.8              4.4 ± 1.1              .537
  TG, mmol/L                       1.3 (0.9, 1.9)         1.1 (0.8, 1.5)         .001
  LDL, mmol/L                      2.7 (2.1, 3.5)         2.6 (1.9, 3.2)         .128
  Hs‐CRP, μg/ml                    4.0 (1.9, 7.2)         6.1 (2.0, 9.8)         .033
  FBG, mmol/L                      6.0 ± 2.0              6.6 ± 1.8              .007
  Homocysteine, μmol/L             16.1 ± 7.2             16.5 ± 10.0            .712
  Uric acid, μmol/L                315.6 ± 108.3          293.9 ± 110.0          .081

Abbreviations: CE, cardioembolism; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; Hs‐CRP, hypersensitive c‐reactive protein; LAA, large artery atherosclerosis; LDL, low‐density lipoprotein; NIHSS, National Institutes of Health Stroke Scale; OTT, onset‐to‐treatment time; SAO, small artery occlusion; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.
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4. DISCUSSION {#brb31426-sec-0013}
=============

In this study, we unveiled that NLR, an affordable and readily available tool, may be a powerful predictor of END in AIS patients being considered for IVT. Our study showed that patients with elevated NLR levels were at increasing risks of developing post‐thrombolysis END, even when controlling for age, proximal arterial occlusion, sICH, malignant edema, and other potential confounders. Furthermore, the optimal cutoff value of NLR to indicate post‐thrombolysis END was 4.43, and its corresponding sensitivity and specificity were 70.9% and 79.3%, respectively. Furthermore, our established nomogram indicated that higher NLR was an indicator of post‐thrombolysis END.

Clinical evidences have shown that, in AIS patients, high NLR levels are associated with increased infarct volume and mortality (Celikbilek, Ismailogullari, & Zararsiz, [2014](#brb31426-bib-0006){ref-type="ref"}; Gökhan et al., [2013](#brb31426-bib-0010){ref-type="ref"}; Tokgoz et al., [2013](#brb31426-bib-0027){ref-type="ref"}). Furthermore, NLR is a predictor of recurrent ischemic stroke and 90‐day poor functional outcome in AIS patients receiving endovascular stroke therapy or IVT or antiplatelet medications (Brooks et al., [2014](#brb31426-bib-0004){ref-type="ref"}; Duan et al., [2018](#brb31426-bib-0008){ref-type="ref"}; Malhotra et al., [2018](#brb31426-bib-0017){ref-type="ref"}; Qun et al., [2017](#brb31426-bib-0021){ref-type="ref"}). In the present study, it is the first time to investigate the relationship between NLR and early functional deterioration in AIS patients with IVT therapy. In accordance with previous studies (Rajajee et al., [2006](#brb31426-bib-0022){ref-type="ref"}; Seners, Turc, Oppenheim, & Baron, [2015](#brb31426-bib-0024){ref-type="ref"}; Thanvi, Treadwell, & Robinson, [2008](#brb31426-bib-0026){ref-type="ref"}), our cohort reported a prevalence of 25.1% in post‐thrombolysis END. We found that NLR revealed its predictive value in the occurrence of post‐thrombolysis END. It is worthwhile to note that, in bridging therapy group, NLR still has great potential as a predictor of END occurrence, suggesting the types of treatment may have minimal effects on the relationship between NLR and END following AIS.

Mechanistically, END is believed to be resulted from biochemical abnormality such as inflammation (Alawneh, Moustafa, & Baron, [2009](#brb31426-bib-0002){ref-type="ref"}; Zhang et al., [2016](#brb31426-bib-0030){ref-type="ref"}). END in patients with lacunar infarction has reported a correlation with high peripheral concentrations of pro‐inflammatory factors, such as IL‐6, TNF‐α, and intercellular adhesion molecule‐1 (Castellanos et al., [2002](#brb31426-bib-0005){ref-type="ref"}). In AIS, it is reported that the inflammatory process is launched within 24 hr at ischemic site and has an important role in exacerbating ischemic damage (Kim, Park, Chang, Kim, & Lee, [2016](#brb31426-bib-0013){ref-type="ref"}; Zhang, Chopp, Chen, & Garcia, [1994](#brb31426-bib-0029){ref-type="ref"}). The inflammatory cytokines and chemokines released from ischemic tissues guide the infiltration of circulating leukocytes, among which neutrophils are the most recognized mediator in ischemic brain injury (Wu et al., [2013](#brb31426-bib-0028){ref-type="ref"}). Neutrophil, the main inflammatory cell of AIS, on one hand, can release free oxygen radicals propagating secondary brain injury in penumbra regions (Ceulemans et al., [2010](#brb31426-bib-0007){ref-type="ref"}). On the other hand, neutrophils are the source of matrix metalloproteinase‐9 (MMP‐9), which can directly result in blood--brain barrier (BBB) breakdown and hemorrhagic transformation (Duan et al., [2018](#brb31426-bib-0008){ref-type="ref"}). These may be significant contributors in the occurrence of END. Additionally, some subtypes of lymphocyte have been reported to be major cerebroprotective immunomodulators after AIS in response to ischemic injury and are involved in reduced infarct volume and improved neurological function (Kim et al., [2012](#brb31426-bib-0014){ref-type="ref"}; Liesz et al., [2013](#brb31426-bib-0016){ref-type="ref"}). Therefore, higher lymphocyte count may be related to lower risks of END. However, single biomarker is prone to be affected by various physiological and pathological conditions (Nash et al., [2014](#brb31426-bib-0019){ref-type="ref"}). NLR, a composite parameter in the combination of neutrophils and lymphocytes, could serve to better reflect immunological activities of the cells and divide patients into comprehensive inflammatory profiles, playing a better role in predicting post‐thrombolysis END in patients with AIS.

Our study has some potential limitations. Firstly, our study was conducted within participants from one single center via strict exclusion criteria, whose results might not be able to generalize to the general population. Secondly, the sample size of the present study was relatively small. Larger cohorts of subjects are needed. Thirdly, it has been proposed that blood cell counts may change during the recovery of ischemic stroke (Iadecola & Anrather, [2011](#brb31426-bib-0012){ref-type="ref"}). To maximally reduce the possible correlation of this effect with our results, blood cell counts were assessed before IVT to minimize the time interval between the onset of stroke and blood sampling. Fourthly, although we found the relationship between NLR and post‐thrombolysis END, there did not exist dynamic examination of the blood cell count of every patient. Blood cell count needed to be examined dynamically in further studies. Finally, data were observational. We were therefore unable to establish a causal relationship between NLR and END after IVT.

In conclusion, from the present study, NLR levels appeared to be positively correlated with post‐thrombolysis END in ischemic stroke patients and can serve as a useful noninvasive biomarker for assessment of END after IVT.
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